Efficacy, safety, and immunogenicity of the AS01E-adjuvanted RSV prefusion F protein vaccine in older adults over three respiratory syncytial virus seasons: a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial

Duration of protection after respiratory syncytial virus (RSV) vaccination is unknown. This study aimed
to evaluate efficacy and safety over three RSV seasons of the AS01E-adjuvanted RSV prefusion F protein-based vaccine
(RSVPreF3 OA) against RSV-related lower respiratory tract disease (RSV-LRTD) in older adults.